Voyageur Pharmaceuticals Ltd. Stock OTC Markets
Stocks
VYYR.F
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0140 USD | 0.00% |
|
0.00% | -89.24% |
| Market Cap | 20.37M 14.59M 12.6M 11.61M 10.87M 1.39B 20.69M 137M 53.46M 675M 54.76M 53.59M 2.34B | P/E Ratio 2024 |
-5.24x | P/E Ratio 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 20.14M 14.43M 12.46M 11.48M 10.75M 1.37B 20.45M 136M 52.86M 667M 54.14M 52.99M 2.31B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
91.6% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 month | -81.33% | ||
| 3 months | -87.50% | ||
| 6 months | -86.00% | ||
| Current year | -89.24% |
| 1 month | 0.01 | 0.08 | |
| Current year | 0.01 | 0.13 | |
| 1 year | 0 | 0.24 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 01/07/2019 |
| Director of Finance/CFO | - | 17/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 17/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Kraws
BRD | Director/Board Member | 62 | - |
Brent Willis
BRD | Director/Board Member | - | 06/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 01/07/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | - | - | 14.55M | ||
| -2.41% | +0.14% | +39.53% | +154.43% | 1,035B | ||
| +1.07% | +3.48% | +53.75% | +50.64% | 574B | ||
| +1.32% | +0.22% | +18.35% | +65.35% | 397B | ||
| +0.58% | +0.77% | +21.19% | +15.95% | 324B | ||
| -0.85% | -0.68% | +23.44% | +14.94% | 281B | ||
| +0.44% | +5.39% | +25.86% | +35.39% | 278B | ||
| +1.66% | +1.20% | -44.41% | -47.37% | 193B | ||
| +0.32% | +1.61% | +19.48% | +63.42% | 191B | ||
| -0.22% | -2.76% | +12.08% | +61.30% | 156B | ||
| Average | +0.20% | +1.68% | +18.81% | +46.00% | 381.1B | |
| Weighted average by Cap. | -0.30% | +2.39% | +28.20% | +71.91% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.34 |
| Net income | -1.71M -1.22M -1.06M -973K -911K -116M -1.73M -11.49M -4.48M -56.57M -4.59M -4.49M -196M | -3.53M -2.53M -2.19M -2.01M -1.88M -240M -3.59M -23.78M -9.27M -117M -9.5M -9.29M -405M |
| Net Debt | -113K -80.67K -69.68K -64.21K -60.1K -7.67M -114K -758K -296K -3.73M -303K -296K -12.92M | -231K -165K -143K -131K -123K -15.7M -234K -1.55M -605K -7.64M -620K -607K -26.45M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYR.F Stock
Select your edition
All financial news and data tailored to specific country editions
















